'Don't eat me' up­start taps Take­da vet on path to the clin­ic; Greg Mayes leaves An­tios for Cana­di­an psy­che­delics play­er

Ne­nad Gr­musa was “re­al­ly hap­py” at Take­da, where he’d been for more than a decade in var­i­ous R&D strat­e­gy and fi­nance po­si­tions. How­ev­er, the more he learned about DEM Bio­Phar­ma, the more in­trigued he be­came by can­cer’s un­ex­plored “don’t eat me” sig­nals.

Jonathan Weiss­man and team launched the apt­ly-named biotech back in June to de­ploy macrophages and oth­er myeloid ef­fec­tor cells against tu­mors by us­ing so-called “don’t eat me” and “eat me” sig­nals, which al­low can­cer cells to evade the im­mune sys­tem.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters